SNORA51: A Promising Drug Target and Biomarker (G677831)

Target Name: SNORA51

NCBI ID: G677831

SNORA51

Other Name(s): ACA51 | Small nucleolar RNA, H/ACA box 51 | small nucleolar RNA, H/ACA box 51

SNORA51: A Promising Drug Target and Biomarker

SNORA51 (ACA51) is a drug target and a biomarker that is being studied for its potential in treating various diseases, including cancer. SNORA51 is a small non-coding RNA molecule that has been shown to play a role in the regulation of cell growth and differentiation.

The discovery and characterization of SNORA51 comes from a research group led by Dr. Xujiong Ye at the University of California, San Diego. Dr. Ye and his team identified SNORA51 as a potential drug target by using a variety of techniques, including RNA sequencing and bioinformatics analysis.

SNORA51 is a RNA molecule that is expressed in various tissues and cells of the body. It has been shown to play a role in the regulation of cell proliferation, cell differentiation, and cell survival. Studies have shown that SNORA51 can interact with and regulate the activity of several transcription factors, including TGF-β1, NF-kappa-B, and SMAD3.

One of the key features of SNORA51 is its ability to alter the levels of RNA stability. SNORA51 has been shown to cause the degradation of RNA molecules by using a mechanism known as microRNA-protein interactions (miRNA-protein interactions). This mechanism is important for the regulation of gene expression and is a potential target for drugs that are designed to interfere with miRNA function.

In addition to its role in RNA stability, SNORA51 has also been shown to play a role in the regulation of cell growth and differentiation. Studies have shown that SNORA51 can cause the growth of cancer cells to be inhibited, and that this effect is dependent on the levels of SNORA51 in the cells.

The potential clinical applications of SNORA51 are vast and varied. As a drug target, SNORA51 has the potential to be used to treat a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. SNORA51 has also been shown to be a potential biomarker for several diseases, including cancer and neurodegenerative diseases.

In addition to its potential clinical applications, SNORA51 also has significant potential as a research tool. The miRNA-protein interactions that SNORA51 uses to regulate RNA stability provide a powerful tool for studying the regulation of gene expression and the role of miRNA in various biological processes.

Overall, SNORA51 is a promising drug target and biomarker that has the potential to revolutionize the field of neuroscience and the treatment of various diseases. Further research is needed to fully understand the role of SNORA51 in the regulation of cell growth and differentiation, and to develop safe and effective drugs that can target SNORA51.

Protein Name: Small Nucleolar RNA, H/ACA Box 51

The "SNORA51 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA51 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets